Forgot your password?

Forgot your username?

database > company
Invendo Medical
Medical Devices & Tech
Peterhofstrasse 3b
Kissing, NY D-86438 Germany
phone:+49 (0)8233 74498 0
fax:+49 (0)8233 74498 15
Symbol Private
Founded 1992
Employees 25
www.invendo-medical.com
Research Sector Medical Devices & Tech
Summary Description
Disposable, easy-to-use and potentially sedationless endoscopes for gastroenterological applications
Management
Berthold Hackl, Chief Executive Officer; Timo Hercegfi, Chief Financial Officer; Dr. Christoph Schnuerer-Patschan, Head of Technical Operations; John J. Cifarelli, Executive VP Global Markets
Keywords
colonoscopy, remote opterated endoscope, sedationless colonscopy,

Comment | Printable Version | Modify profile |
Updated: Aug. 10, 2011

Description
Invendo medical aims to become a globally leading developer and distributor of novel disposable endoscopy products in the field of gastroenterology, including a single-use, potentially sedationless colonoscope for both diagnostic and therapeutic interventions.
Products / Services
First product to be marketed will be a single-use, handheld-controlled and potentially sedationless colonoscope - the invendoscope.
Technology / Differentiation
Combining a highly flexible endoscope with proprietary inverted sleeve technology, this device minimizes forces applied to the intestinal wall during colonoscopy, thereby enabling performance of the procedure without pain and sedation (and, potentially, with partial assistance from non-specialists).
Market / Customers
Approximately 20 million colonoscopies are performed each year; since many eligible individuals elect not to undergo the full procedure, this represents a fraction of the true market potential.
Competitors / Substitutes / Alternatives
Olympus Medical, Pentax, Fujinon
Funding
VC-funded (TVM Capital, Wellington Partners, Heidelberg Innovation, 360? Capital Partners).
Status
The company anticipates the launch of its product in the first half of 2010, and is seeking $20 million in expansion capital for the end of 2009/early 2010 to fund U.S. market introduction efforts.